The optimal medical strategy for prevention of thromboembolic events after bioprosthetic
aorta valve replacement (BAVR) remains controversial.
The aim of this trial was to compare warfarin therapy (target INR of 2.0 to 3.0) against
aspirin 150mg daily as antithrombotic therapy for the first three months after BAVR with or
without concomitant coronary artery bypass grafting (CABG). The aim was to evaluate
thromboembolic complications, bleeding complications and death.